FAST FACTS

The DERMABOND® PRINEO® Skin Closure System **vs** exofin fusion®

Chemence Medical markets exofin fusion®, a skin closure system promoted as an equivalent to the DERMABOND® PRINEO® Skin Closure System. While both products include mesh and an adhesive, **their adhesive formulations and supporting data greatly differ.**

DERMABOND® delivers consistent results from the brand you trust.

Formulation

exofin fusion®

Includes a 2-octyl cyanoacrylate (2-OCA) monomer, an initiator, and thickener[1,2]

DERMABOND®

- In addition to a highly purified 2-OCA, DERMABOND® is developed with specific ratios of an initiator and additives, that together, provide strong, flexible closure with microbial barrier protection[3,4]
- exofin fusion® relies on DERMABOND®'s clinical data to support their claims;[1] however, since DERMABOND®'s formulation is unique and proprietary, exofin fusion cannot be expected to provide the same clinical results as DERMABOND®

Strength

exofin fusion® Statement

Marketing materials state that exofin fusion® was found to be stronger in every category, including Wound Closure, Lap Shear, Tensile Strength, and T-Peel.[1] However, this statement is supported by data that is unavailable to the public.

DERMABOND® Response

- While exofin fusion® supports their claims with non-public data, the DERMABOND® Portfolio is backed by an extensive body of evidence, including 5,718 patients across 57 Randomized Controlled Trials (RCTs)*†
- DERMABOND PRINEO System is ~33% stronger than staples and ~40% stronger than 4-0 suture[5‡]

Cost Savings

exofin fusion® Statement

Marketing materials state: "Save your operating room time and money while improving patient outcomes: lower healthcare costs, faster OR procedures, lower readmission risk."[1]

DERMABOND® Response

- There is no exofin fusion®–specific data supporting these claims. Some claims are not referenced at all, while others are supported by DERMABOND PRINEO System data—NOT exofin fusion® data[1]
- DERMABOND PRINEO System is associated with lower readmission risk and healthcare savings as demonstrated in both a retrospective study AND economic models[6,7]
  - In a retrospective study, DERMABOND PRINEO System was associated with significantly reduced readmission rates vs skin staples in total knee arthroplasty[6]
  - Economic models have shown DERMABOND PRINEO System may provide healthcare savings vs conventional wound closure methods[7]

There are many topical skin adhesives (TSAs) to choose from, but only the DERMABOND Portfolio has been trusted for over 20 years and backed by a breadth of clinical data no other TSA can match!*†

*DERMABOND ADVANCED® Adhesive, DERMABOND PRINEO System, and DERMABOND® Mini Topical Skin Adhesive test equivalent or superior to DERMABOND Adhesive in head-to-head testing for microbial barrier, wound-bursting strength, tensile strength, flexibility, durability, viscosity, drying time, water vapor transmission rate, water resistance, and physician satisfaction.
†Based on published literature in PubMed and SCOPUS, using only RCTs that evaluated the use of the product in a manner consistent with intended indication.
‡Study performed ex vivo.

Why choose DERMABOND® PRINEO® Skin Closure System

The DERMABOND PRINEO System is a novel skin closure device that combines DERMABOND® Topical Skin Adhesive with a self-adhering mesh patch to provide:

Protection

A flexible, watertight, microbial barrier with 99% protection in vitro for 72 hours against organisms commonly responsible for surgical site infection[8]*

Strength

Significantly greater skin-holding strength than skin staples or subcuticular suture[9†]

Cost Savings

Potential cost savings due to decreased resource utilization in the post-acute care setting[7‡]

Greater overall satisfaction for surgeons and patients[10§]

- Patients with DERMABOND PRINEO System agreed that they were more satisfied with the appearance of their incision compared to skin staples[10§]
- Surgeons agreed that they worry less about patients with DERMABOND PRINEO System taking care of their incision at home compared to patients with staples[10§]

Choose the Right DERMABOND® for You

DERMABOND® PRINEO® Skin Closure System

Greater skin holding strength than skin sutures and staples in 22 – 60 cm sizes for longer, open incisions[9]

(22 cm)

(42 cm)

(60 cm)

DERMABOND ADVANCED® Topical Skin Adhesive

Trusted quality and proven efficacy for mid-to-large incisions—up to 15 cm in length[3,4]

DERMABOND® Mini Topical Skin Adhesive

Proprietary DERMABOND® formulation in an economically efficient size for small incisions—up to 4 cm in length

*Staphylococcus epidermidis, Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, and Enterococcus faecium.
†In an ex-vivo study, more load in N was required to create a 3 ±1 mm gap between skin edges approximated with DERMABOND PRINEO System, than with subcuticular 4-0 MONOCRYL Suture or PROXIMATE® Ethicon Endo-Surgery skin staples (p=0.00).
‡Demonstrated in an economic model assessing DERMABOND PRINEO System in knee and hip arthroplasty.
§Double-blinded quantitative market research study comparing surgeon experience with DERMABOND PRINEO System and skin staples in total knee arthroplasty (TKA). N=88 patients; N=83 orthopaedic surgeons. 90% c.I. Fielded June/July 2017.

For complete indications, contraindications, warnings, precautions, and adverse reactions, please reference full package insert.

References: 1. Exofin fusion® skin closure system brochure. Chemence Medical, Inc. **2.** U.S. Food & Drug Administration. Exofin® High Viscosity Tissue Adhesive 510(k) letter: K152476. February 9, 2016. **3.** Singer AJ, Perry LC, Allen Jr. RL. In vivo study of wound-bursting strength and compliance of topical skin adhesives. *Acad Emerg Med.* 2008;15(12):1290-94. **4.** Bhende S, Rothenburger S, Spangler DJ, Dito M. In vitro assessment of microbial barrier properties of DERMABOND® Topical Skin Adhesive. *Surg Infect (Larchmt).* 2002;3:251-257. **5.** AST-2014-0246: Study to compare the tissue holding strength of DERMABOND® PRINEO® 22 cm Skin Closure System (DP22) to conventional wound closure techniques. Ethicon, Inc. **6.** STRATAFIX PRINEO TKA Premier Study Results. Jan 18, 2017. Ethicon, Inc. **7.** Sadik, K, Flener J, Gargiulo J, et al. A U.S. hospital budget impact analysis of a skin closure system compared with standard of care in hip and knee arthroplasty. Presented at the ISPOR 22nd Annual International Meeting, May 20-24, 2017. **8.** Su W. Study Report for in vitro evaluation of microbial barrier properties of DERMABOND ProTape. Report Number 06TR071. December 4, 2006. Ethicon, Inc. **9.** Kumar, A. AST-2012-0290: Study to compare the tissue holding strength of PRINEO™ skin closure system with conventional wound closure techniques. October 11, 2012. Ethicon, Inc. **10.** PRINEO Claims Research Quant Detail. August 16, 2017. Ethicon, Inc.

ETHICON
PART OF THE Johnson & Johnson FAMILY OF COMPANIES
Shaping the future of surgery